Journal article
Visual impairment and blindness due to macular diseases globally: A systematic review and meta-analysis
JB Jonas, RRA Bourne, RA White, SR Flaxman, J Keeffe, J Leasher, K Naidoo, K Pesudovs, H Price, TY Wong, S Resnikoff, HR Taylor
American Journal of Ophthalmology | Published : 2014
Abstract
PURPOSE: To estimate the number of people visually impaired or blind due to macular diseases except those caused by diabetic maculopathy. DESIGN: Meta-analysis. METHODS: Based on the Global Burden of Disease Study 2010 and ongoing literature research, we examined how many people were affected by vision impairment (presenting visual acuity <6/18, ‡3/60) and blindness (presenting visual acuity <3/60) due to macular diseases, with diabetic maculopathy excluded. RESULTS: In 2010, of 32.4 million blind people and 191 million vision-impaired people, 2.1 million (95% uncertainty interval [UI]: 1.9, 2.7) people were blind, and 6.0 million (95% UI: 5.2, 8.1) million were visually impaired due to macu..
View full abstractGrants
Funding Acknowledgements
ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST, and the following were reported. Dr Jonas is a consultant for Allergan Inc, Merck Sharp & Dohme Inc, Alimera Co, Boehringer Ingelheim Co, and Sanofi Co and is a patent holder with CellMed AG, Alzenau, Germany. The study was supported by the Bill and Melinda Gates Foundation (Seattle, Washington; Fight for Sight); the Fred Hollows Foundation (Alexandria, New South Wales, Australia); and the Brien Holden Vision Institute (Sydney, Australia). Design and conduct of study (J.B.J., R.R.B., R.A.W., S.R.F., J.K., J.L., K.N., K.P., H.P., T.Y.W., S.R., H.R.T.); Collection; management, analysis, and interpretation of data (J.B.J., R.R.B., R.A.W., S.R.F., J.K., J.L., K.N., K.P., H.P., T.Y.W., S.R., H.R.T.); and Preparation, review, or approval of the manuscript (J.B.J., R.R.B., R.A.W., S.R.F., J.K., J.L., K.N., K.P., H.P., T.Y.W., S.R., H.R.T.). Gretchen Stevens (World Health Organization, Geneva, Switzerland) profoundly helped in the statistical analysis of the data. Benita J O'Colmain (ICF International Inc, Rockville, MD, USA) assisted with the incorporation of microdata from several large population-based studies. The principal investigators of these and other studies are thanked for authorizing unpublished study data to be used in this project. Catherine Michaud (Institute for Health Metrics and Evaluation, Seattle, WA, USA) and Colin Mathers (World Health Organization, Geneva, Switzerland) greatly assisted in the communications between the Global Burden of Disease Core Group and the Global Burden of Disease Vision Loss Expert Group. Donatella Pascolini (World Health Organization, Geneva, Switzerland) kindly assisted in retrieval of some unpublished data sources. A list of members of the Vision Loss Expert Group appears at http://www.anglia.ac.uk/ruskin/en/home/microsites/veru/other_research_areas/global_burden_of_diseases.html.